Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02412579 · ClinicalTrials.gov registry record
Genetic Profiling of Liver Cancer in Patients Undergoing Liver Transplantation
A clinical trial of Hepatocellular Carcinoma, sponsored by Baylor Research Institute.
- Completed
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT02412579 is a study of Hepatocellular Carcinoma that has completed, run by Baylor Research Institute. The registered enrollment target is 40 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02412579, a study of Hepatocellular Carcinoma, has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether genetic markers unique to liver cancer are present and to assess usefulness as a diagnostic tool.
Conditions Studied
Interventions
- OTHER None - Standard of Care
Study Locations (1)
Texas
- Baylor University Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-03 |
| Est. Completion | 2022-03-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02412579
The ClinicalTrials.gov registry entry for NCT02412579 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (84% lower). The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which None - Standard of Care is the first listed.
NCT02412579 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02412579 about?
NCT02412579 is a clinical study titled "Genetic Profiling of Liver Cancer in Patients Undergoing Liver Transplantation". The purpose of this study is to determine whether genetic markers unique to liver cancer are present and to assess usefulness as a diagnostic tool.
What is the current status of trial NCT02412579?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2015-03. Estimated completion is 2022-03-17.
What conditions does trial NCT02412579 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT02412579?
The interventions under investigation include: None - Standard of Care (OTHER).
Who is sponsoring clinical trial NCT02412579?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02412579 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Molecular Basis of Pediatric Liver Cancer
RECRUITING
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.